Pantheon Infrastructure shifts to capital management as dividend cover raises concerns
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.
Arix Bioscience chief executive Robert Lyne departs midway through a strategic review with the shares trading at a 38% discount.
Symphony International, a badly-performing Asia private equity fund, announces ‘orderly realisation’ of its assets after failing to revive its heavily discounted share price.
Garry Channon's unusual Netflix-holding UK value fund stages first half turnaround despite its new position in Hotel Chocolat suffering a share price meltdown.
The dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, however, problems with LumiraDx continue to be a concern for analysts.
Dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, but problems with LumiraDx continue to concern analysts.
Dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, but problems with LumiraDx continue to concern analysts.
Abrdn is closing its historic investment trust savings plans and annoying investors with the transfer of their holdings to Interactive Investor, the online stockbroker it owns.
Life Science Reit is looking at creative ways of funding for the future as manager Simon Farnsworth remains optimistic following its launch into a tough market.
Nearly two-thirds of the renewables fund’s independent shareholders vote to retain its board, resisting removal efforts by dismissed fund manager ThomasLloyd Global.
The trust formerly known as Woodford Patient Capital sells 22% of its publicly quoted holdings to pay for share buybacks to help rerate its depressed stock.
Developed by Moore-Wilson